Merck Highlights the P-II (WaveLINE-007) Study Data of Zilovertamab Vedotin to Treat Diffuse Large B-Cell Lymphoma at ASH 2024
Shots:
- The dose escalation P-II (WaveLINE-007) trial assessed the zilovertamab vedotin (1.75mg/kg, 2mg/kg, 2.25mg/kg, IV, Q3W) plus cyclophosphamide, doxorubicin, prednisone & rituximab (R-CHP) in treatment-naïve DLBCL patients (n=36)
- Study depicted an overall CRR of 97.2%, with 100% CR at 1.75mg/kg & 2.25mg/kg dose as well as 93.3% at 2mg/kg; ORR mirrored these results at a median follow-up of 17.6mos.; 12mos. DoR was 93.5% with mDoR not reached. The recommended dose found is 1.75mg/kg
- Serious TRAEs occurred in 11% with Grade 3-4 TRAEs in 58% of all. Most common AEs were neutropenia, nausea, anemia & diarrhea
Ref: Merck | Image: Merck
Related News:- Merck and Ridgeback Biotherapeutics Begin P-III (MOVe-NOW) Trial of Lagevrio (Molnupiravir) to Treat COVID-19 in High-Risk Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
